Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

OSI Buying Cancer Rights To Serono's Novantrone For $55M

March 13, 2003

By Aaron Lorenzo

Oncology company OSI Pharmaceuticals Inc. is fronting $55 million to Serono SA for U.S. marketing rights to the cancer indications of a long-approved but oft-shuffled drug. (BioWorld Today)

OSI Buying Cancer Rights To Serono's Novantrone For $55M

March 13, 2003

By Aaron Lorenzo

Oncology company OSI Pharmaceuticals Inc. is fronting $55 million to Serono SA for U.S. marketing rights to the cancer indications of a long-approved but oft-shuffled drug. (BioWorld Today)

Peptimmune Nets $41.2 Million In Series A Financing Round

March 12, 2003

By Aaron Lorenzo

Peptimmune Nets $41.2 Million In Series A Financing Round

March 12, 2003

By Aaron Lorenzo

Isotechnika Compound Looks Promising After Psoriasis Study

March 11, 2003

By Aaron Lorenzo

Isotechnika Compound Looks Promising After Psoriasis Study

March 11, 2003

By Aaron Lorenzo

Interleukin Cedes Majority Interest To Alticor Through Collaboration

March 7, 2003

By Aaron Lorenzo

PanCel Gets Telomerase License From Geron For Diabetes Program

March 7, 2003

By Aaron Lorenzo

Interleukin Cedes Majority Interest To Alticor Through Collaboration

March 7, 2003

By Aaron Lorenzo

PanCel Gets Telomerase License From Geron For Diabetes Program

March 7, 2003

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...